SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

Search

Orion Oyj (Class B)

Closed

66.55 -0.15

Overview

Share price change

24h

Current

Min

66.55

Max

67.65

Key metrics

By Trading Economics

Income

-12M

61M

Sales

-80M

355M

P/E

Sector Avg

25.565

39.564

EPS

0.44

Dividend yield

2.57

Profit margin

17.287

Employees

3,943

EBITDA

202M

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.57%

2.40%

Market Stats

By TradingEconomics

Market Cap

3.4B

8.9B

Previous open

66.7

Previous close

66.55

Orion Oyj (Class B) Chart

Past performance is not a reliable indicator of future results.

Related News

11 Jul 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FCC Approves U.S. Cellular Sale to T-Mobile

11 Jul 2025, 17:28 UTC

Major Market Movers

SharpLink Gaming Gains on Ethereum Purchase

11 Jul 2025, 16:57 UTC

Earnings

BASF Cuts Outlook on Global Economy Uncertainty

11 Jul 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 Jul 2025, 19:46 UTC

Acquisitions, Mergers, Takeovers

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 Jul 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 Jul 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 Jul 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 Jul 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 Jul 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 Jul 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 Jul 2025, 16:42 UTC

Earnings

BASF Cuts Outlook on Global Economic Uncertainty

11 Jul 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 Jul 2025, 16:05 UTC

Earnings

BASF Will Publish Half-Year Results on July 30

11 Jul 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11 Jul 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 Jul 2025, 16:03 UTC

Earnings

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 Jul 2025, 16:02 UTC

Earnings

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 Jul 2025, 16:01 UTC

Earnings

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 Jul 2025, 16:00 UTC

Earnings

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 Jul 2025, 15:59 UTC

Earnings

BASF Cuts 2025 Earnings View

11 Jul 2025, 15:58 UTC

Earnings

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 Jul 2025, 15:57 UTC

Earnings

BASF 2Q EBIT Before Special Items EUR810M

11 Jul 2025, 15:54 UTC

Earnings

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 Jul 2025, 15:54 UTC

Earnings

BASF 2Q Sales Fell 2.1% on Year

11 Jul 2025, 15:53 UTC

Earnings

BASF 2Q Sales EUR15.77B

11 Jul 2025, 15:52 UTC

Earnings

BASF: This Was in Line With Consensus Estimates

11 Jul 2025, 15:52 UTC

Earnings

BASF 2Q Ebitda Before Special Items EUR1.77B

11 Jul 2025, 15:49 UTC

Earnings

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 Jul 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer Comparison

Price change

Orion Oyj (Class B) Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.